Insider Selling: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells 2,804 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Tsveta Milanova sold 2,804 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Agios Pharmaceuticals Trading Up 4.7 %

Shares of AGIO stock opened at $35.12 on Wednesday. Agios Pharmaceuticals, Inc. has a 12-month low of $20.96 and a 12-month high of $62.58. The business’s fifty day simple moving average is $47.15 and its 200-day simple moving average is $45.63. The company has a market cap of $2.00 billion, a PE ratio of 3.09 and a beta of 0.87.

Analyst Ratings Changes

Several research analysts have issued reports on AGIO shares. Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Scotiabank increased their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Royal Bank of Canada upped their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Finally, Raymond James reissued an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $56.33.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC acquired a new stake in Agios Pharmaceuticals in the second quarter worth about $37,000. Quest Partners LLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at approximately $40,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 363 shares in the last quarter. CWM LLC grew its position in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in Agios Pharmaceuticals during the 3rd quarter valued at approximately $146,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.